Companies
GILD
GILEAD SCIENCES, INC.
Gilead Sciences develops and markets pharmaceutical treatments across multiple therapeutic areas, including antiviral drugs for HIV and hepatitis C, oncology therapies, and other disease categories. The company operates both marketed drugs and pipeline programs, with a portfolio spanning from approved medications like Biktarvy and Harvoni to cell therapy products like Yescarta and investigational candidates such as Jyseleca. Gilead's development stage ranges from commercial-stage products generating revenue to earlier-stage pipeline programs in development.
$130.84+26.09%1Y
GILD · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 3HIV-1-infection
Phase 3HIV-1-infection
Phase 3HIV-1-infection
Phase 3Breast Cancer
Phase 3Locally Advanced or Unresectable Metastatic Breast Cancer
Phase 3Stage IV Breast Cancer
Phase 3Breast Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Metastatic Urothelial Cancer
Phase 2Head and Neck Squamous Cell Carcinoma
Phase 3PD-L1 Positive
Phase 3Non-Small Cell Lung Cancer
Phase 3PD-L1 Negative
Phase 3Breast Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Metastatic Urothelial Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Advanced Non-Small Cell Lung Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 2Advanced Non-Small Cell Lung Cancer
Phase 2Metastatic Urothelial Cancer
Phase 2Head and Neck Squamous Cell Carcinoma
Phase 3Non-Small Cell Lung Cancer
Phase 3Endometrial Cancer
Phase 3Breast Cancer
Phase 3Pre-Exposure Prophylaxis of HIV-1 Infection
Phase 2/3Acquired Immune Deficiency Syndrome (AIDS)
Phase 2/3HIV Infections
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 3Pre-Exposure Prophylaxis of HIV-1 Infection
Phase 2Metastatic Urothelial Cancer
Phase 3PD-L1 Positive
Phase 3PD-L1 Negative
Phase 3Breast Cancer
Phase 3Breast Cancer
Phase 3HIV-1-infection
Phase 3HIV-1-infection
Phase 2Pre-Exposure Prophylaxis of HIV Infection
Phase 3HIV Pre-exposure Prophylaxis
Phase 2HIV-1-infection
Phase 2Pre-Exposure Prophylaxis of HIV Infection
Phase 3HIV Pre-exposure Prophylaxis
Phase 2HIV-1-infection
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 3PD-L1 Positive
Phase 3Non-Small Cell Lung Cancer
Phase 3Locally Advanced or Unresectable Metastatic Breast Cancer
Phase 3Stage IV Breast Cancer
Phase 3PD-L1 Negative
Phase 3Breast Cancer
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Head and Neck Squamous Cell Carcinoma
Phase 3Endometrial Cancer
Phase 3PD-L1 Positive
Phase 3Non-Small Cell Lung Cancer
Phase 3Locally Advanced or Unresectable Metastatic Breast Cancer
Phase 3Stage IV Breast Cancer
Phase 3PD-L1 Negative
Phase 3Breast Cancer
Phase 2Metastatic Urothelial Cancer
Phase 3Breast Cancer
Phase 3PD-L1 Positive
Phase 3Non-Small Cell Lung Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 3Non-Small Cell Lung Cancer
Phase 3HIV-1-infection
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 3HIV-1-infection
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2Advanced Solid Tumor
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2HR+/HER2- Metastatic Breast Cancer
Phase 2Metastatic Urothelial Cancer
Phase 3Endometrial Cancer
Phase 2Metastatic Solid Tumor
Phase 2Solid Tumor
Phase 3PD-L1 Positive
Phase 3Locally Advanced or Unresectable Metastatic Breast Cancer
Phase 3Stage IV Breast Cancer
Phase 3PD-L1 Negative
Phase 3Breast Cancer
Phase 3Primary Biliary Cholangitis
Phase 3Primary Biliary Cholangitis
Phase 3Primary Biliary Cirrhosis
Phase 3Primary Biliary Cirrhosis
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 3Pre-Exposure Prophylaxis of HIV Infection
Phase 3Chronic Hepatitis B
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 3Breast Cancer
Phase 2Advanced Non-Small Cell Lung Cancer
Phase 2Metastatic Urothelial Cancer
Phase 2Head and Neck Squamous Cell Carcinoma
Phase 3Non-Small Cell Lung Cancer
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2/3HIV-1-infection
Phase 2HIV-1-infection
Phase 2Metastatic Urothelial Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Pre-Exposure Prophylaxis of HIV Infection
Phase 2Ulcerative Colitis
Phase 2Metastatic Urothelial Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Chronic Hepatitis Delta
Phase 2HIV-1-infection
Phase 2HIV-1-infection
Phase 2HIV-1-infection
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Advanced Non-Small Cell Lung Cancer
Phase 2Advanced Non-Small Cell Lung Cancer
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2Breast Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Chronic Hepatitis B
Phase 2HIV-1-infection
Phase 2Ulcerative Colitis
Phase 2Lung Cancer
Phase 2Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2Resectable Non-Small-Cell Lung Cancer
Phase 2HIV-1-infection
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.